Providers

The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.

A reimbursable, team-based remote blood pressure monitoring program significantly improved hypertension control in patients with multiple chronic conditions.

The benefit of trabectedin plus olaparib to all-comers with soft tissue sarcoma was marginal, but the response was more pronounced in certain subgroups.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

Community oncology practices can enhance their presence in the community by offering innovative service lines such as multispecialty infusions, and by offering enrollment assistance for better outcomes.

Leaders of OneOncology share how the managed services organization empowers independent oncology practices through advanced technology, clinical trials, and value-based care, enhancing patient-focused cancer treatment.

The meeting included new evidence and expert insights on hormone therapy, AI, and the expanding role of GLP-1 therapies in cardiovascular care.

Leaders describe how shared data, theranostics programs, and coordinated clinical trials support independent practices and advance value-based cancer care.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.

How strategic partnerships in oncology can enhance patient care by addressing diverse needs through collaboration.

The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.

Experts discuss the evolving dynamics between payers and providers in oncology, emphasizing value-based care, data transparency, and collaborative reform opportunities.

Oncology leaders warn that declining reimbursements and policy gaps threaten patient access and drive inequities in cancer care.

Lerodalcibep-liga subcutaneous injection is now approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Psychotherapy is key in reducing risk of depression relapse when tapering antidepressant medication.

Cervical cancer screening adherence drops below 10%, highlighting confusion over evolving guidelines and significant disparities in HPV awareness.

A review of 560 FDA-approved drugs found the FDAAA did not change overall time to first postmarket safety action, but some actions occurred earlier.

As value-based care mandates expand, a new survey highlights documentation burdens and burnout risks.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

McKesson's report highlights key trends in community oncology, emphasizing patient-centered care, precision medicine, and the need for innovative clinical trials.

Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.